Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Clinical Practice Guideline – Prevention of Chemotherapy and Radiotherapy-Induced Nausea and Vomiting

2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting

ESMO Open. 2024;9(2):102195.
Herrstedt J, Clark-Snow R, Ruhlmann CH, et al., on behalf of the participants of the MASCC–ESMO Consensus Conference 2022

  • Nausea and vomiting are considered amongst the most troublesome adverse events for patients receiving antineoplastics.
  • The guideline covers emetic risk classification, prevention and management of treatment-induced nausea and vomiting.
  • The Consensus Committee consisted of 34 multidisciplinary, health care professionals and three patient advocates.
  • Recommendations are based on evidence-based data (level of evidence) and the authors’ collective expert opinion (grade).
  • All recommendations are for the first course of antineoplastic therapy; modifications may be needed in subsequent courses.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.